We studied the clinical efficacy of Bevacizumab combined with argon green laser in treating fundus macular edema. From May 2009 to April 2013, 78 patients seeking treatment for macular edema in the First Affiliated Hospital of Nanchang University were enrolled in this study. Patients were randomly divided into two groups: i) The experimental group (n=39) and the control group (n=39). Patients i...

OBJECTIVE Intravitreal Bevacizumab (Avastin, Genentech Inc., San Francisco, CA) (IVB) has been shown to cause regression of neovessels in proliferative diabetic retinopathy due to its anti-angiogenic effects. This study was performed to investigate the role of Avastin as an adjunct to the management of patients with proliferative diabetic retinopathy undergoing pars plana vitrectomy. METHODOL...

Aim: To study the reduction in macular oedema Central Retinal Vein Occlusion cases following Intravitreal injection of Bevacizumab using Spectral Domain Optical Coherence Tomography. Methods: 50 patients diagnosed with more than 300 microns on Tomography ( SD-OCT) ,who attended to Out patient Department Government Regional Eye Hospital (GREH) between January 2020 June were administered Injectio...

BACKGROUND: Adult vitelliform macular dystrophy results in loss of central vision. The use systemic sildenafil has been proven to increase choroidal blood flow. This is a report favorable long-term treatment outcome using for patient with adult onset dystrophy. CASE PRESENTATION: A 55-year-old woman presenting bilateral subretinal lesions was initially assessed by full-field electroretinogram, ...

Many therapeutic monoclonal antibodies (mAbs) are clinically administered through intravenous infusion after mixing with a diluent, e.g., saline, 5% dextrose. Such a clinical setting increases the likelihood of interactions among mAb molecules, diluent, and plasma components, which may adversely affect product safety and efficacy. Avastin® (bevacizumab) and Herceptin® (trastuzumab), but not Rem...

BACKGROUND The cost utility of treatments of age-related macular degeneration (AMD) is commonly assessed using health state transition models defined by levels of visual acuity. However, there is evidence that another measure of visual function, contrast sensitivity, may be better associated with utility than visual acuity. This paper investigates the difference in cost effectiveness resulting ...

BACKGROUND Branch retinal vein occlusion is a frequent cause of visual loss with currently insufficient treatment options. We evaluate the effect of Bevacizumab (Avastin) treatment in patients with macular edema induced by branch retinal vein occlusion. METHODS Retrospective analysis of 32 eyes in 32 patients with fluorescein angiography proven branch retinal vein occlusion, macular edema and...

Dear Editor, Myopic choroidal neovascularisation (mCNV) is one of the most common causes of permanent central visual loss in patients with high myopia,1 and its natural history results in the development of chorioretinal atrophy around the regressed mCNV, causing further progressive central visual loss.2 Therefore there is a need to fi nd treatment options which will not only regress the mCNV b...